Annual Financial Report 30 June 2025 25 Statement of profit or loss and other comprehensive income 26 Statement of financial position 27 Statement of changes in equity 28 Statement of cash flows 29 Notes to the financial statements 44 Consolidated entity disclosure statement 45 Directors’ declaration 46 Independent auditor’s report to the members of Noxopharm Limited 50 Shareholder information General information The financial statements cover Noxopharm Limited as a consolidated entity consisting of Noxopharm Limited and the entities it controlled at the end of, or during, the year. The financial statements are presented in Australian dollars, which is Noxopharm Limited’s functional and presentation currency. Noxopharm Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business are: Registered Office: Principal Place of Business: Level 5 60 Linksley Ave 126 Phillip Street Glenhaven NSW 2156 SYDNEY NSW 2000 A description of the nature of the consolidated entity’s operations and its principal activities are included in the directors’ report, which is not part of the financial statements. The financial statements were authorised for issue, in accordance with a resolution of directors, on 29 September 2025. The directors have the power to amend and reissue the financial statements. Corporate Governance Statement The Corporate Governance Statement is available on the Company’s website at http://www.noxopharm.com Annual Report 2025 24
RkJQdWJsaXNoZXIy MjE2NDg3